V. Cereda | AMiner学者主页

185P Focus on HER2-positive Metastatic Colorectal Cancer (HER2+ Mcrc): A Real-World Retrospective Analysis

M.A. Calegari,V. Formica,F. Zoratto,G. Arrivi, A. Torsello, M. Polito,V. Picone,A. Emiliani,V. Cereda,M. Schirripa,G. Caira,A. Spring,

2024Annals of Oncology（2024）

引用

AI阅读

2Focus on HER2-positive Metastatic Colorectal Cancer (her2+mcrc): A Real-World Retrospective Analysis

M. A. Calegari,V. Formica,F. Zoratto,G. Arrivi, A. Torsello, M. Polito,V. Picone,A. Emiliani,V. Cereda,M. Schirripa,G. Caira,A. Spring,

2024ANNALS OF ONCOLOGY（2024）

引用

AI阅读

31571 Ideal Body Mass Index (BMI) is Significantly Different Between Curatively Resected and Metastatic Colorectal Cancer (CRC) Patients on Chemotherapy

V. Formica,S. Pellicori,H. T. Arkenau, C. Morelli,J. Lucchetti,A. Nardecchia,S. Riondino,P. Ferroni,V. Cereda,M. Tesauro,F. Guadagni,M. Roselli

2015European Journal of Cancer（2015）

引用

AI阅读

4Predictive Role of Neutrophil/Lymphocyte Ratio (nlr) for Oxaliplatin Efficacy in Metastatic Pancreatic Cancer Patients (Pts)

V. Formica, C. Morelli,P. Ferroni,A. Nardecchia,M. Tesauro,V. Cereda,F. Guadagni,M. Roselli

Aim: To investigate the prognostic and predictive value of the inflammatory index Neutrophil/Lymphocyte ratio (NLR) in two homogeneous groups of chemotherapy-naïve metastatic pancreatic adenocarcinoma (PA) pts treated with either gemcitabine (GEM) or GEM + oxaliplatin (GEMOXA).

2014Annals of Oncology（2014）

引用

AI阅读

5Peripheral CD45RO, PD1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab/5FU/irinotecan (B-FOLFIRI)